Talimogene laherparepvec: overview, combination therapy and current practices.
Talimogene laherparepvec (T-VEC, Imlygic®, Amgen, CA, USA) is an oncolytic herpes simplex type 1 virus used as intralesional therapy for unresectable metastatic melanoma in a cutaneous, subcutaneous or nodal location. Talimogene laherparepvec selectively replicates within and lyses tumor cells while producing granulocyte macrophage colony-stimulating factor, which may promote an immune mediated antitumor response. The US FDA approved T-VEC in late 2015 following Phase I-III trials that demonstrated safety and efficacy. Future directions for T-VEC include combination therapies with other systemic immunotherapies such as anti-CTLA-4 antibody and anti-PD-1 drugs. Current National Comprehensive Cancer Network (NCCN) practice guidelines have added T-VEC as a primary treatment for stage IIIB/C and stage IVM1a melanoma patients.
["O'Donoghue|Cristina|C|", 'Doepker|Matthew P|MP|', 'Zager|Jonathan S|JS|']
Imlygic intralesional therapy metastatic melanoma GM-CSF clinical trial oncolytic therapy talimogene laherparepvec (T-VEC)